Ezetimibe, on the other hand, has been shown to partially protect against albuminuria and CKD progression in Col4a3−/− mice by reducing CD36-dependent fatty acid uptake and triglyceride content [26]. This evidence concerns the gene COL4A3 and chronic kidney disease.